G
GramEye
AI-automated bacterial testing for antimicrobial resistance
About GramEye
Grameye operates in the healthcare and biotechnology sector, focusing on combating drug-resistant bacteria using artificial intelligence (AI) and advanced microbial analysis. The company serves healthcare providers, research institutions, and pharmaceutical companies by offering innovative solutions that identify and analyze drug-resistant bacteria. Grameye's business model revolves around providing subscription-based access to its AI-driven platform, which helps clients make informed decisions in their fight against antimicrobial resistance. Revenue is generated through subscription fees, consulting services, and partnerships with healthcare organizations. The company leverages cutting-edge technology to address a critical and growing issue in global health, positioning itself as a leader in the field of microbial resistance.
Source: Dealroom company dataAt a glance
- Founded
- 2020
- Headquarters
- Ibaraki, Japan
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Deepcore
NEDO
Station Ai
Samurai Incubate
SMBC Venture Capital
Senshu Ikeda Capital
NES
Beyond Next Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GramEye on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GramEye on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.